Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Conditions
- Metastatic Melanoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Hodgkin Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Melanoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Rhabdomyosarcoma
- Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Refractory Hodgkin Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Melanoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Rhabdomyosarcoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Melanoma
Interventions
- BIOLOGICAL: Ipilimumab
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Nivolumab
- OTHER: Pharmacological Study
Sponsor
National Cancer Institute (NCI)